Advertisement

Picture [iito] No Tracking 650x80px
Document › Details

SmartDyeLivery GmbH. (10/15/20). "Press Release: Successful Multi-million Financing Round for SmartDyeLivery GmbH". Erfurt & Jena.

Organisations Organisation SmartDyeLivery GmbH
  Organisation 2 Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT)
  Group Thuringia (govt region)
Products Product nanoparticle technology
  Product 2 venture capital
Person Person Lehmann, Marc (SmartDyeLivery GmbH 20602 Managing Director)
     


Current financing round with a consortium of existing and new investors completed, bm-t beteiligungsmanagement thüringen gmbh increases lead investment


SmartDyeLivery GmbH has successfully completed its most recent financing round in the mid-single-digit million range. In addition to bm-t beteiligungsmanagement thüringen gmbh (bm|t), which increased its lead investment, the Stiftung für Technologie, Innovation und Forschung Thüringen (STIFT) and three new private investors invested in SmartDyeLivery´s development of innovative nanotherapies. The new group of private investors was formed with the support of the business angel and finance & M&A consultant Louis Moser from Munich/Grünwald, who again invested in the company.

SmartDyeLivery develops a platform technology for the targeted transport of active pharmaceutical ingredients. Based on functionalized nanotransporters, active substances are specifically delivered to affected organs of the body. "Our goal is to develop nanoparticles with high cell specificity in which drugs can be encapsulated in order to treat diseases in a more precise way, minimize or even entirely avoid side effects and ultimately save human lives," said Dr. Marc Lehmann, CEO of SmartDyeLivery. Especially in the context of the company´s first application of nanotransporters for a specific therapy for septic liver failure, the investment enables important development steps on the path to market approval.


About SmartDyeLivery:

Jena-based SmartDyeLivery GmbH is developing a universal platform technology based on functionalized nanoparticles that can be used to transport active ingredients or other cargos to the desired site of action. The company´s aim is to provide new therapeutic options for diseases that have previously been untreatable or extremely difficult to treat. The innovative, patented technology can also be used for diagnostic or theragnostic applications.

Further information can be found at: www.smartdyelivery.de/en/


About bm|t:

Erfurt-based bm|t is a subsidiary of the Thüringer Aufbaubank and the leading address for equity investments in Thüringen, Germany. bm|t currently manages nine funds with a total volume of around EUR 420 million, which invest in innovative companies across almost all sectors and in all phases of company development.

Further information about bm|t is available at: www.bm-t.com


About the STIFT:

The STIFT supports, promotes and accompanies innovative technology-oriented and innovative business start-ups in Thüringen, Germany within the ThEx project. The STIFT also invests in selected high-tech start-ups as a co-investor. For its investment activities, the degree of innovation of the founding idea and the entrepreneurial potential form the main criteria.

Further information is available at: www.stift-thueringen.de


Contact persons:

Dr. Marc Lehmann
CEO
SmartDyeLivery GmbH
Botzstraße 5
07743 Jena

Stefan Jahn
Senior Investment Manager
bm-t beteiligungsmanagement thüringen gmbh
Gorkistraße 9
99084 Erfurt

   
Record changed: 2020-10-16

Advertisement

Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for SmartDyeLivery GmbH


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [iito] Made Without Love 650x80px




» top